The EU approvals committee has recommended Teva Pharmaceutical Industries Ltd.'s humanized interleukin-5 antagonist monoclonal antibody, Cinqaero (reslizumab), for use as an add-on therapy in adult patients with severe eosinophilic asthma, whose disease has been inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
This is in line with the label granted by the US FDA in March to the product as Cinqair, which...





